MedTrace Logo

99Tc-MDP for Thyroid-Associated Ophthalmopathy

NCT03948191 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-05-15

No results posted yet for this study

Summary

To investigate the efficacy，safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.

Conditions

  • Thyroid-Associated Ophthalmopathy

Interventions

DRUG

Methylprednisolone

500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.

DRUG

99Tc-MDP(99Technetium-Methylenediphosphonate Injection)

15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.

Sponsors & Collaborators

  • Dalian University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2018-12-30
Completion
2019-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03948191 on ClinicalTrials.gov